Influenza virus DNA vaccine - PowderMed

Drug Profile

Influenza virus DNA vaccine - PowderMed

Alternative Names: Influenza virus vaccine - PowderMed; PF-4522625

Latest Information Update: 25 Apr 2009

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PowderMed
  • Class Antivirals; Influenza virus DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 03 Oct 2006 Phase-I clinical trials in Influenza virus infections in USA (Intradermal)
  • 03 Oct 2006 PowderMed has initiated enrolment in a phase I trial for Influenza Virus Infections in the United Kingdom
  • 08 Jun 2006 Phase I data have been added to the adverse events and Viral Infections immunogenicity section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top